Source: Folha BV

The doctor works at Albert Einstein hospital in São Paulo and recommends the use of hydroxychloroquine associated with zinc and azithromycin, an antibiotic indicated for respiratory infections

The oncologist doctor Nise Yamaguchi has gained prominence in the medical scene for being a great defender of hydroxychloroquine in the early stages of the symptoms of the coronavirus.

In an interview with Rádio Folha, the doctor explained that the drug that is used to treat malaria and lupus, and that it has been tested in patients with Covid-19 and has a positive result.

The doctor works at Albert Einstein hospital in São Paulo and recommends the use of hydroxychloroquine associated with zinc and azithromycin, an antibiotic indicated for respiratory infections.

“It treats patients in the initial phase, if the patient is medicated at the very beginning of the symptoms, the disease may not reach the acute phase, where the use of respirators is necessary.

The most indicated is that the medication starts with the symptoms, and not in asymptomatic cases or in people who live with positive patients “she explained during the interview.

“For treatment of early diseases, this is already well defined and people are benefiting, there is a study with corticosteroids for patients who are starting with inflammation, because covid has several phases, the first with viral proliferation, but the studies clinical trials have not yet been carried out with ivermectin and nitazoxanide. What we prioritize is that patients undergo treatment as soon as the first symptoms occur, only 5% of those patients who have had this treatment have evolved to severe cases, in severe cases it is also a indication the use of anticoagulants “said.

The doctor also commented on the telemedicine initiative, when doctors talk to patients and make prescriptions over the phone or the internet.

“A prior evaluation is important, but it is not our reality, we know that prophylaxis is the set of measures used in order to prevent or decrease the risk of transmitting a disease” she said.

Oncologist doctor Nise Yamaguchi

Related:

Due to significantly improved outcome, Henry Ford Health System continues hydroxychloroquine study

Indonesia Claims Five Drug Combos, including HCQ, Reduce Novel Coronavirus

FDA ENABLES use of HCQ in a weird round about win – by revoking EUA. Says they never restricted it.

After 13 ER visits, woman with COVID-19 needed to travel to Dallas for hydroxychloroquine treatments

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

A Conversation With Dr. Brian Tyson – The Chloroquine Wars Part XLI

The data from the vaccine trials must be recalculated under the lens that some of the serious adverse events (SAEs) should be treated as COVID-19 cases.
There may not be any vaccine efficacy in the data at all if some of the post-vaccination deaths are due to vaccine-induced COVID-19. It could even be the case that the mortality efficacy goes negative. My implied lives saved calculations put this easily in the realm of possibility. The only way to know is for authorities to organize and compile the data. And while a risk analysis is certainly due after more than six months of hundreds of millions of doses delivered, there is little indication authorities have bothered with the process. That’s more than a bit unsettling.

Read More »

Dr. Brian Tyson, USA: Hydroxychloroquine – Data, Strategies and Success Treating over 6000 Covid Patients

We continue to delve extensively into the COVID-19 data with esteemed statistician, Mathew Crawford. In this episode, we take a closer look at the use of early treatment and its success. Mathew has been researching the data from Dr. Brian Tyson, who has successfully treated over 6000 patients who contracted COVID throughout the pandemic. It is my great honor to have Dr. Tyson here on this episode to not only discuss the data, but also the strategies that he has been using throughout the pandemic.

Read More »